Preferred Label : nirogacestat;

MeSH note : an antineoplastic agent;

CISMeF synonym : PF 03084014; PF 3084014; 2-(5,7-difluoro-1,2,3,4-tetrahydronaphthalen-3-ylamino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide;

MeSH hyponym : PF03084014; PF-03084014; PF3084014; PF-3084014;

Is substance : O;

UNII : QZ62892OFJ;

Details


Main resources

You can consult :


https://ansm.sante.fr/tableau-acces-derogatoire/nirogacestat
2025
false
false
false
France
French
administration, oral
nirogacestat
ogsiveo
summary of product characteristics
package leaflet
guidelines for drug use
Desmoid Tumors
Refractory Desmoid Fibromatosis
nirogacestat

---
https://www.has-sante.fr/jcms/p_3576525/fr/ogsiveo-nirogacestat-tumeurs-desmoides
2025
false
false
false
France
nirogacestat
treatment outcome
insurance, health, reimbursement
Tumor Progression
Refractory Desmoid Fibromatosis
adult
administration, oral
Gamma Secretase Inhibitors
nirogacestat
evaluation of the transparency committee
ogsiveo
Desmoid Tumors

---
Nous contacter.
03/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.